Leaders of important House and Senate Committees, both bipartisan in nature, are seeking information from experts on best practices to develop a regulatory framework governing CBD.
Bipartisan legislators have issued a Request for Information to gather information from experts on the subject. The FDA is under pressure to develop rules that will allow hemp-derived cannabinoids to be sold as food or dietary supplements.
Leading the effort are the chairs and ranking members from the Senate Health, Education, Labor, and Pensions Committee (HELP), and the House Energy & Commerce Committee, who invite people to comment on different issues related to FDA and CBD.
They are asking to provide feedback about FDA’s view that it does not have a regulatory pathway allowing it to regulate CBD in food or as a supplement. Also, they want feedback on the FDA’s position regarding the rise of intoxicating cannabinoids such as delta-8 THC, which are synthesized using legal CBD.
NEW: Bicameral Health Committee leaders @FrankPallone, @cathymcmorris, @SenSanders, and @SenBillCassidy issue request for information regarding FDA regulation of CBD https://t.co/YqMhZVkRta
Energy & Commerce Democrats July 27, 2020
The RFI states that “since hemp was descheduled five years ago consumers, manufacturers and policy makers have sought clarification regarding the legal status CBD.” Farmers, food and drink groups, and state regulatory agencies have communicated their policy priorities to Congress. There are still questions about how to best provide a legal path to market for CBD-based products.
They also want to know about the existing market dynamics, and how state and federal regulatory relationships interact. The RFI includes 29 questions and is available through August 18. The RFI is open until August 18.
The lawmakers stated that they were evaluating the potential of a regulatory path for hemp-derived CBD product which prioritizes consumer protection and provides certainty for the U.S. Market. “We are looking forward to working with stakeholders interested in this process.”
The RFI is signed by Senate HELP Committee Chairwoman Cathy McMorris Rodgers, (R. WA) and Ranking Members Bill Cassidy and Frank Pallone.
Respondents are asked to comment on a number of issues including potential potency limitations, warning labels and minimum age for sale, manufacturing, testing, ingredient restrictions, adverse event reporting, and possible THC content.
A question asked was, “How can a regulatory framework take into account CBD products that are marketed with other substances which may alter or enhance CBD’s effects (e.g. caffeine, melatonin etc. ).”
Another states that “other products that are not cannabinoids, but have been marketed and raised safety concerns by some people, FDA has regulated them without substance-specific regulatory frameworks (e.g. kratom, caffeine, etc. ).”
The lawmakers want to know “How FDA has dealt with these products?” How might CBD-specific products affect these products?
The request was sent out on the same date that a House Oversight Subcommittee conducted its first ever hearing on FDA’s lack of action on CBD regulations.
—
Marijuana Moment tracks more than 1,000 cannabis and drug policy bills that have been introduced in state legislatures, and Congress. Patreon supporters who pledge at least $25/month gain access to our interactive charts, maps and hearing calendar.
Discover more about our marijuana bills tracker. Become a Patreon supporter to gain access.
—
Rep. James Comer, R-KY, who chairs the Oversight Committee has harshly criticized FDA for its announcement in January that the agency would not be developing CBD regulation . The FDA stated that it was not able to develop such regulations and that it would need congressional action.
In April, the congressman announced that his panel would launch an investigation into this matter and requested that FDA provide documents related to their decision not to regulate the cannabinoid. The congressman had expressed his intention to deal with the lack of rules even before the agency took that decision.
A report by the U.S. Department of Agriculture , released in April, shows that the hemp industry suffered a significant decline in 2022. And stakeholders blame the FDA for its refusal to regulate CBD products.
In March , bipartisan members of Congress re-filed two separate bills which are intended to regulate hemp derivatives such as CBD for use in dietary supplements, food and beverage additives and other products.
Sens. Ron Wyden, Rand Paul (R.KY), Jeff Merkley and Earl Blumenauer (D.OR) filed separate legislation last week to remove the regulatory barriers FDA claims prevent it from allowing CBD sale.
The Hemp Access and Consumer Safety Act , which was introduced in the last Congress, but never advanced, would exempt hemp, hemp-derived CBD, or any substance containing other ingredients derived from hemp from federal restrictions while allowing officials to implement labeling and packing rules.
The FDA announced that it would not be regulating CBD just days after released its finalized guidance which focuses on the development of cannabis-based medicines and details the process as well as unique considerations that scientists should take into account when it comes hemp and marijuana.
The agency has been praised by both parties for its first-ever guidelines on the development of psychedelic drugs. The FDA is also actively working on reviewing the federal scheduling for marijuana, as per a directive given by President Joe Biden in 2013.
Bipartisan lawmakers celebrate the passage of veterans medical marijuana access and psychedelics research provisions
Photo by Brendan Cleak.
The article Senate and House Lawmakers from both parties seek expert input on CBD regulations as FDA faces pressure to act first appeared on Marijuana Moment.
